|1.||Aviles, P: 2 articles (10/2001 - 12/2000)|
|2.||Gargallo-Viola, D: 2 articles (10/2001 - 12/2000)|
|3.||Pateman, A: 1 article (10/2001)|
|4.||Gómez De Las Heras, F: 1 article (10/2001)|
|5.||San Roman, R: 1 article (10/2001)|
|6.||Guillén, M J: 1 article (10/2001)|
|7.||Caballero, J: 1 article (12/2000)|
|8.||Martinez, A: 1 article (12/2000)|
|9.||Jimenez, E: 1 article (12/2000)|
|10.||Stevens, D A: 1 article (07/2000)|
|1.||Body Weight (Weight, Body)
10/01/2001 - "Linearity of the main pharmacokinetic parameters was demonstrated after intravenous dosing of the representative compound GM 193663 at 10 and 20 mg/kg of body weight in rats. "
12/01/2000 - "After a subcutaneous dose of 50 mg/kg of body weight to mice, the maximum level in serum, area under the concentration-time curve, half-life, and clearance for GM193663 and GM237354 were 51.8 and 23 microg/ml, 79.5 and 46 microg. "
|2.||Pneumocystis Pneumonia (Pneumocystis carinii Pneumonia)
07/01/2000 - "Systemic coccidioidomycosis was established in female CD-1 mice infected with Coccidioides immitis, and therapy was begun on day 4 with either GM193663, GM211676, GM237354, fluconazole, or no treatment; compounds were given twice daily orally for 19 days at 20 or 100 mg/kg/day. "
07/01/2000 - "Efficacies of sordarin derivatives GM193663, GM211676, and GM237354 in a murine model of systemic coccidioidomycosis. "
12/01/2000 - "In summary, GM193663 and GM237354 are new sordarin derivatives that may potentially play a major role in the treatment of candidiasis and PCP. "
12/01/2000 - "The in vivo activity of GM193663 and GM237354 was studied in mouse models of disseminated candidiasis and aspergillosis and in a rat model of pneumocystosis. "
|4.||Dihydrotachysterol (AT 10)